The estimated Net Worth of Michael P Bailey is at least $6.72 Milion dollars as of 20 December 2022. Mr. Bailey owns over 276,746 units of AVEO Pharmaceuticals Inc stock worth over $5,102,505 and over the last 14 years he sold AVEO stock worth over $28,319. In addition, he makes $1,589,640 as President, Chief Executive Officer a Director at AVEO Pharmaceuticals Inc.
Michael has made over 7 trades of the AVEO Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 276,746 units of AVEO stock worth $1,248,124 on 20 December 2022.
The largest trade he's ever made was exercising 276,746 units of AVEO Pharmaceuticals Inc stock on 20 December 2022 worth over $1,248,124. On average, Michael trades about 17,429 units every 153 days since 2010. As of 20 December 2022 he still owns at least 340,167 units of AVEO Pharmaceuticals Inc stock.
You can see the complete history of Mr. Bailey stock trades at the bottom of the page.
Michael P. Bailey serves as President, Chief Executive Officer, Director of the Company. Mr. Bailey joined our company in September 2010 as our Chief Commercial Officer and was named our Chief Business Officer in June 2013. Prior to joining our company, Mr. Bailey served as senior vice president, business development and chief commercial officer at Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of oncology medicines, from August 2008 to September 2010. From 1999 to 2008, Mr. Bailey worked at ImClone Systems Incorporated, a biopharmaceutical company focused on the development and commercialization of treatments for cancer patients. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and PORTRAZZA® (necitumumab). In addition, Mr. Bailey was a member of the strategic leadership committees for ImClone and its North American and worldwide partnerships and led its commercial organization, most recently as senior vice president of commercial operations. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., a biotechnology company, from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of Smith-Kline Beecham’s executive marketing development program, where he held a variety of commercial roles from 1992 to 1997, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at the University of Notre Dame.
As the President, Chief Executive Officer a Director of AVEO Pharmaceuticals Inc, the total compensation of Michael Bailey at AVEO Pharmaceuticals Inc is $1,589,640. There are no executives at AVEO Pharmaceuticals Inc getting paid more.
Michael Bailey is 54, he's been the President, Chief Executive Officer a Director of AVEO Pharmaceuticals Inc since 2020. There are 6 older and 7 younger executives at AVEO Pharmaceuticals Inc. The oldest executive at AVEO Pharmaceuticals Inc is Robert Young, 80, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON, MA, 02108.
Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over $6,664,465 worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth $217,351,881 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $9,488,415. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth $1,248,124.
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include: